The safety profile of DUPIXENT in patients aged 12 to 17 years through Week 16 was similar to the safety profile from studies in adults with atopic dermatitis.
300 mg Q2W
|Conjunctivitisa||8 (10)||4 (5)|
|Injection site reaction||7 (9)||3 (4)|
|Gastroenteritis viral||3 (4)||1 (1)|
|Pharyngitis streptococcal||2 (2)||0|
|Viral upper respiratory tract infection||2 (2)||1 (1)|
|Sinusitis bacterial||2 (2)||0|
|Oropharyngeal pain||2 (2)||1 (1)|
|Nausea||2 (2)||1 (1)|
|Abdominal pain upper||2 (2)||1 (1)|
|Ligament sprain||2 (2)||0|
|Procedural pain||2 (2)||0|
aIncludes atopic keratoconjunctivitis, conjunctivitis, conjunctivitis allergic, conjunctivitis bacterial, and conjunctivitis viral.
Fewer adolescent patients treated with DUPIXENT developed skin infections compared with placebo in Trial 6 (11% vs 20%)2,3
The long-term safety of DUPIXENT in adolescents was assessed in an open‑label extension trial (Trial 7) through Week 521
Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs and/or until a parasitic (helminth)
infection resolves in a patient who does not respond to anti-helminth treatment.1
DUPIXENT clinical trials included adult and adolescent patients with a history of immunosuppressant use2,3
DUPIXENT is not a steroid treatment or an immunosuppressant1
There is no requirement for initial lab testing or ongoing lab monitoring according to the Prescribing Information1
Avoid use of live vaccines with DUPIXENT2
aRefers to systemic nonsteroidal immunosuppressants.
bThese patients were considered nonresponders.